Balloon Valvuloplasty Devices Market – By Product Type (Standard, Cutting, Scoring Balloon), Application (Aortic Valve Stenosis, Pulmonary Valve Stenosis), Age Group (Pediatric, Adult), End-use (Hospitals, ASCs) – Global Forecast (2024 – 2032)

Balloon Valvuloplasty Devices Market Size

Balloon valvuloplasty devices market size was valued at around USD 2.4 billion in 2023 and is estimated to grow at 4.8% CAGR from 2024 to 2032. Balloon valvuloplasty devices are medical devices used in interventional cardiology procedures to treat valvular heart diseases, particularly stenosis (narrowing) of heart valves. These devices consist of a balloon catheter system that is inserted into the heart through a blood vessel, typically the femoral artery, and navigated to the site of the diseased valve.
 

The rising geriatric population is a significant driver for the balloon valvuloplasty devices market. For instance, according to the World Health Organization (WHO), in 2023, the number of persons aged 65 years or older worldwide is expected to double over the next three decades. The elderly population will reach 1.6 billion in 2050, accounting for more than 16% of the global population. Valvular heart disease, such as aortic stenosis and mitral stenosis, becomes more prevalent with age, particularly among the elderly population. As individuals age, their heart valves may degenerate, calcify, or develop other structural abnormalities, leading to valve stenosis or regurgitation.
 

Moreover, increasing use of heart valve devices, rising adoption of prosthetic heart valves, advancement in structural heart devices, rising healthcare expenditure globally, government initiatives and funding, and increasing education & awareness, are the factors supporting the growth of the market.
 

Balloon Valvuloplasty Devices Market Trends

The increasing prevalence of valvular heart disease is a significant driver for balloon valvuloplasty devices industry. Risk factors for valvular heart disease (VHD), including pulmonary arterial hypertension, hypercholesterolemia, diabetes, and smoking, are becoming increasingly prevalent worldwide.  
 

• According to the Multidisciplinary Digital Publishing Institute (MDPI), in 2023, the prevalence of rheumatic heart disease, the most common valvular heart disease (affecting approximately 41 million people), has been rising in developing nations, likely due to the expansion of the young adult population.
   
• Balloon valvuloplasty procedures have expanded beyond their traditional indications to include a broader spectrum of patients with various types and severities of valvular stenosis or regurgitation. Improved cardiology information system, device technology, procedural techniques, and patient selection criteria have widened the applicability of balloon valvuloplasty, making it a viable treatment option for a larger proportion of patients with VHD.
   
• Moreover, the prevalence of valvular heart disease is not limited to developed countries, it is also increasing in emerging markets due to demographic shifts, urbanization, and changes in lifestyle factors. As healthcare infrastructure improves and access to advanced medical treatments expands in these regions, the demand for balloon valvuloplasty devices is expected to grow.
   

Balloon Valvuloplasty Devices Market Analysis  

Based on product type, the market is segmented into standard balloon, cutting balloon, scoring balloon, high-pressure balloon, and low-pressure balloon. The standard balloon segment is estimated to account for USD 1.5 billion by the end of 2032.
 

• Standard balloons are versatile and can be used in a variety of valvuloplasty procedures, including aortic and pulmonary valve interventions. Their broad applicability makes them suitable for treating a wide range of patients with different types and severities of valvular heart disease, contributing to their high market demand.
   
• Further, these balloons are often more cost-effective compared to newer, specialized balloon technologies such as cutting or scoring balloons.
   
• Standard balloons have demonstrated efficacy in achieving valve dilation and symptom relief in patients with valvular stenosis. For instance, clinical studies and real-world evidence have shown that standard balloon valvuloplasty can effectively improve valve function and hemodynamics, leading to clinical improvement and enhanced quality of life for patients, thereby accelerating the segmental growth.

Based on application, the balloon valvuloplasty devices market is divided into aortic valve stenosis, and pulmonary valve stenosis. The aortic valve stenosis segment accounted for USD 1.4 billion in 2023.
 

• Aortic valve stenosis is one of the most common types of valvular heart disease, particularly among the elderly population. As people age, the risk of developing calcific aortic valve stenosis increases, contributing to a larger patient population in need of treatment.
   
• For instance, according to the European Society of Cardiology, in 2022, it was estimated that there are around 300,000 people living with severe aortic stenosis, representing nearly 1.5% of the population aged 55 and older in UK.
   
• Aortic valve stenosis can cause symptoms such as chest pain, dyspnea (shortness of breath), syncope (fainting), and decreased exercise tolerance. Balloon valvuloplasty offers a minimally invasive treatment option to relieve symptoms and improve quality of life in patients with symptomatic aortic stenosis who are not candidates for surgical valve replacement.
   
• Balloon valvuloplasty is often performed in high-risk or inoperable patients who are not suitable candidates for surgical aortic valve replacement (SAVR) or transcatheter aortic valve replacement (TAVR). These patients may have multiple comorbidities, advanced age, or other factors that increase their surgical risk, making balloon valvuloplasty a preferred treatment option.
   
• Thus, such aforementioned factors are expected to augment the segmental growth.
   

Based on age group, the market is divided into pediatric and adult. The adult segment accounted for a market share of 61.3% in 2023.
 

• Aortic valve stenosis is one of the most common types of valvular heart disease, particularly among the elderly population. As people age, the risk of developing calcific aortic valve stenosis increases, contributing to a larger patient population in need of treatment.
   
• Technological advancements in balloon valvuloplasty devices have made the procedure safer and more effective for adults, encouraging their use in this demographic. These advancements include the development of smaller balloons, improved materials, and better imaging techniques.
   
• Adults are generally more aware of their health conditions and have easier access to healthcare services compared to children. This awareness and accessibility lead to a higher likelihood of adults seeking treatment for valvular heart disease, including balloon valvuloplasty.
   
• Further, balloon valvuloplasty has been performed in adults for a longer time compared to children, resulting in more clinical evidence supporting its efficacy and safety in this demographic. Additionally, healthcare providers may have more experience and expertise in performing the procedure in adults, further contributing to its popularity in this segment.
   

Based on end-use, the balloon valvuloplasty devices market is segmented into hospitals, ambulatory surgical centres, specialty clinics, and other end-users. The hospitals segment held a market size of USD 949.8 in the year 2023.
 

• Hospitals typically have specialized facilities and equipment necessary to perform balloon valvuloplasty procedures. These facilities include cardiac catheterization labs and operating rooms equipped with advanced imaging technologies such as fluoroscopy and echocardiography, which are essential for guiding the procedure.
   
• These settings employ healthcare professionals with specialized training and expertise in interventional cardiology and cardiac surgery. These professionals, including interventional cardiologists, cardiac surgeons, and cardiac anesthesiologists, have the skills and experience required to perform balloon valvuloplasty safely and effectively.
   
• Hospitals have access to a wide range of resources, including medical devices, pharmaceuticals, and support services, which are necessary for performing balloon valvuloplasty procedures. This access allows hospitals to offer state-of-the-art treatments and ensure the availability of essential resources during the procedure. Thus, preceding to the growth of the market.

U.S. balloon valvuloplasty devices market is anticipated to grow at CAGR of 4.4% during the analysis timeframe.
 

• Valvular heart disease, such as aortic stenosis and mitral stenosis, is prevalent in the U.S. due to factors such as an aging population and lifestyle-related risk factors. This high prevalence of valvular heart disease drives the demand for balloon valvuloplasty procedures and devices in the country.
   
• For instance, according to Population Reference Bureau, in 2024, the number of people in the U.S. aged 65 and older is projected to increase from 58 million in 2022 to 82 million by 2050.
   

Germany market is anticipated to witness lucrative growth between 2024 – 2032.
 

• The country has a well-developed healthcare system known for its high-quality medical care and advanced medical technology. The country boasts modern hospitals, clinics, and specialized cardiac centers equipped with state-of-the-art facilities for diagnosing and treating cardiovascular conditions, including valvular heart disease.
   
• Germany is a global leader in medical device manufacturing and innovation. Many companies specialize in the development and production of cardiovascular devices, including balloon valvuloplasty devices. These companies invest heavily in research and development to create cutting-edge products that meet the highest standards of quality and efficacy.
   

Japan balloon valvuloplasty devices market is expected to grow significantly over the years.
 

• Japan is known for its innovation in medical device manufacturing and development. Many Japanese companies specialize in producing high-quality cardiovascular devices, including balloon valvuloplasty devices. These companies invest heavily in research and development to create innovative products that meet the stringent standards of quality and efficacy.
   
• Further, valvular heart disease is relatively common in Japan, particularly among the elderly population. Conditions such as aortic stenosis and mitral stenosis contribute to the demand for balloon valvuloplasty procedures and devices in the country.
   

UAE balloon valvuloplasty devices industry is anticipated to witness lucrative growth between 2024 – 2032.
 

• UAE has been investing significantly in its healthcare infrastructure, with the development of modern hospitals, specialized clinics, and medical centers equipped with state-of-the-art technology. This infrastructure supports advanced cardiovascular procedures, including balloon valvuloplasty, contributing to market growth.
   
• Moreover, UAE has a relatively affluent population with high levels of disposable income and access to private healthcare services. This population segment is willing to invest in advanced medical treatments, including minimally invasive procedures, driving market demand for these devices.
   

Balloon Valvuloplasty Devices Market Share

The balloon valvuloplasty devices industry is highly competitive, marked by several players striving for market dominance. Providers offer comprehensive devices with improved efficiency and affordability. This includes advancements in reading, raw material, data reporting, sensor design, and customization. Competition is driven by factors such as the quality, reliability, performance, cost, and compliance with regulatory standards. Strategic partnerships with companies and healthcare networks play a crucial role in market positioning.
 

Balloon Valvuloplasty Devices Market Companies

Some of the eminent market participants operating in the balloon valvuloplasty devices industry include:

• Abbott Laboratories
• B. Braun Melsungen AG
• Becton, Dickinson, and Company
• Boston Scientific Corporation
• Cardinal Health, Inc.
• Cook Medical Inc.
• Edwards Lifesciences Corporation
• Innomed Medical Development Ltd.
• Jotech GmbH
• Medtronic plc
• Microport Scientific Corporation
• Numed Canada Inc.
• NuMED Inc.
• Osypka Medical GmbH
• Teleflex Incorporated
   

Balloon Valvuloplasty Devices Industry News:

• In December 2022, Abbott announced the launch of its latest generation transcatheter aortic valve implantation (TAVI) system, NavitorTM, making the minimally invasive device available for people in India with severe aortic stenosis that are at high or extreme surgical risk. This launch expanded the product portfolio in the field of ballon valvuloplasty and helped to increase the geographical foothills, thereby increased sales of the company.
   
• In February 2022, Boston Scientific Corporation announced the close of its acquisition of Baylis Medical Company Inc., a company that offers advanced transseptal access solutions as well as guidewires, sheaths and dilators used to support catheter-based left-heart procedures and provides support in heart operation and valvuloplasty. Thus, its enhanced the product landscape of the company, thereby helped to generate the revenue.
   

The balloon valvuloplasty devices market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Product Type

• Standard balloon
• Cutting balloon
• Scoring balloon
• High-pressure balloon
• Low-pressure balloon

Market, By Application

• Aortic valve stenosis
• Pulmonary valve stenosis

Market, By Age Group

• Pediatric
• Adult

Market, By End-use

• Hospitals
• Ambulatory surgical centres
• Specialty clinics
• Other end-users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East and Africa